ABVX is a readout-gated biotech with positive Phase 3 induction data, a much stronger cash position after the 2025 offering, and one big unresolved question: can obefazimod's maintenance data turn runway into a real ulcerative-colitis franchise?
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
